Detalhe da pesquisa
1.
Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch.
J Infect Dis
; 226(10): 1683-1687, 2022 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36124696
2.
Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch.
Open Forum Infect Dis
; 9(10): ofac411, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36213724